Investor Presentaiton
16
Investor presentation
Full year 2022
Financial outlook for 2023
Sales growth - at CER
Expectations
1 February 2023
13% to 19%
Sales growth - reported
Operating profit growth - at CER
Around 4 percentage points lower
13% to 19%
Operating profit growth - reported
Around 5 percentage points lower
Financial items (net)
Effective tax rate
Free cash flow
Gain of around DKK 2.4 billion
19% to 21%
DKK 60 to 68 billion
Novo NordiskⓇ
Note: Changes since last highlighted in bold
The financial outlook is based on an assumption of a continuation of the current business environment and given the current scope of business activities and has been prepared assuming that currency exchange rates remain at the level as of 27 January 2023View entire presentation